Next Article in Journal
Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients
Next Article in Special Issue
Effect of Obesity and High-Density Lipoprotein Concentration on the Pathological Characteristics of Alzheimer’s Disease in High-Fat Diet-Fed Mice
Previous Article in Journal
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma
 
 
Review
Peer-Review Record

The Asparaginyl Endopeptidase Legumain: An Emerging Therapeutic Target and Potential Biomarker for Alzheimer’s Disease

Int. J. Mol. Sci. 2022, 23(18), 10223; https://doi.org/10.3390/ijms231810223
by Mingke Song
Reviewer 1:
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(18), 10223; https://doi.org/10.3390/ijms231810223
Submission received: 16 August 2022 / Revised: 30 August 2022 / Accepted: 2 September 2022 / Published: 6 September 2022
(This article belongs to the Special Issue Advance on the Research of Alzheimer's Disease)

Round 1

Reviewer 1 Report

Minor revision

Comments for author File: Comments.pdf

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The manuscript reviews the overactivation of asparaginyl endopeptidase (AEP) in different neuropathological processes of Alzheimer's disease (AD). The manuscript is interesting, well written and updated. Since late events of AD are characterized by neuronal death, the authors should also investigate the potential role of AEP in neuronal death processes. This information can stimulate the study and development of new neuroprotective drugs for AD.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop